Novo Nordisk reported Phase 3 results showing its next‑generation metabolic combination, CagriSema (semaglutide + cagrilintide), reduced blood sugar and produced greater weight loss than semaglutide (Wegovy) in people with type 2 diabetes. The company said CagriSema achieved superior A1c reductions and, in completer analyses, produced roughly double‑digit weight loss relative to Wegovy. The trial enrolled more than 2,700 patients and used conventional efficacy and conservative "treatment‑regimen" estimands to reflect real‑world performance. Novo has already filed for obesity approval and is pursuing diabetes indications; the Phase 3 readout bolsters its regulatory case and sharpens the commercial contest with Eli Lilly’s Zepbound and other next‑gen metabolic combos. Trial data were presented by Novo Nordisk and summarized in company releases; detailed peer‑reviewed data and regulatory submissions will determine timing and labeling. Clinicians and investors will watch safety, dose tolerability, and comparative effectiveness versus Lilly’s agents as regulators evaluate approvals.